share_log

UBS Initiates Coverage On Fulgent Genetics With Neutral Rating, Announces Price Target of $35

UBS Initiates Coverage On Fulgent Genetics With Neutral Rating, Announces Price Target of $35

瑞银以中性评级启动对富金遗传学的报道,宣布目标股价为35美元
Benzinga ·  2023/12/07 06:06

UBS analyst Dan Leonard initiates coverage on Fulgent Genetics (NASDAQ:FLGT) with a Neutral rating and announces Price Target of $35.

瑞银分析师丹·伦纳德以中性评级开始报道富尔金特遗传学(纳斯达克股票代码:FLGT),并宣布目标股价为35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发